

Katherine McMahan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4278784/publications.pdf>

Version: 2024-02-01

38
papers

6,759
citations

279701

23
h-index

289141

40
g-index

50
all docs

50
docs citations

50
times ranked

11044
citing authors

#	ARTICLE	IF	CITATIONS
1	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JV0159921.	1.5	5
2	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 1124-1128.	1.9	15
3	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
4	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 603, 493-496.	13.7	326
5	Durability and expansion of neutralizing antibody breadth following Ad26.COVS2.S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
6	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. <i>Science Translational Medicine</i> , 2022, 14, eabn6150.	5.8	57
7	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	4.7	27
8	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
9	A homologous or variant booster vaccine after Ad26.COVS2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
10	Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. <i>Med</i> , 2022, 3, 262-268.e4.	2.2	117
11	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
12	Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments. <i>Veterinary Pathology</i> , 2022, , 030098582210957.	0.8	2
13	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	2.9	4
14	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	3
15	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021, 12, 1474.	5.8	26
16	Immunogenicity of the Ad26.COVS2.S Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
17	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection. <i>Journal of Virology</i> , 2021, 95, .	1.5	24
18	Protective efficacy of Ad26.COVS2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40

#	ARTICLE	IF	CITATIONS
19	Immunogenicity of Ad26.COVID-19 vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
20	Low-dose Ad26.COVID-19 protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
21	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. <i>Journal of Virology</i> , 2021, 95, e0040421.	1.5	34
22	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
23	Immunity elicited by natural infection or Ad26.COVID-19 vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	5.8	32
24	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	5.8	15
25	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVID-19 Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	13.9	192
26	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , 2021, 95, e0097421.	1.5	12
27	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	68
28	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
29	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 2010-2012.	13.9	228
30	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
31	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
32	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020, 26, 1694-1700.	15.2	275
33	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
34	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
35	Lack of therapeutic efficacy of an antibody to \hat{I}^{\pm}_{4} \hat{I}^{\pm}_{7} in SIVmac251-infected rhesus macaques. <i>Science</i> , 2019, 365, 1029-1033.	6.0	31
36	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	5.1	124

#	ARTICLE	IF	CITATIONS
37	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature, 2018, 563, 360-364.	13.7	246
38	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	5.8	106